Votrient (pazopanib) — United Healthcare
Renal cell carcinoma (RCC)
Initial criteria
- Diagnosis of renal cell carcinoma (RCC) AND (disease has relapsed OR Stage IV disease OR disease is advanced)
- OR Diagnosis of von Hippel-Lindau (VHL)-associated renal cell carcinoma
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Votrient therapy
Approval duration
12 months